NCT03641131 is a clinical trial in Aspergillus Infection, sponsored by Taiwan Liposome Company.

Who is sponsoring NCT03641131?

NCT03641131 is sponsored by Taiwan Liposome Company.

What condition does NCT03641131 study?

NCT03641131 studies Aspergillus Infection, Febrile Neutropenia, Candida Infection, Fungal Infection, Cryptococcal Infections.

Is NCT03641131 still recruiting?

NCT03641131 is currently completed. Last updated 7 January 2021.

Last reviewed 2021-01-07 · How we verify

NCT03641131

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ampholipad Real-World Data in Taiwan

Completed Last updated 7 January 2021

What this trial tests

trial in Aspergillus Infection in 102 participants. Completed in 8 January 2019.

Timeline

9 September 2018

Primary endpoint
2 January 2019

8 January 2019

Quick facts

Lead sponsor	Taiwan Liposome Company
Status	Completed
Study type	OBSERVATIONAL
Enrollment	102
Start date	9 September 2018
Primary completion	2 January 2019
Estimated completion	8 January 2019
Sites	6 locations across Taiwan

Conditions studied

Aspergillus Infection — all drugs for Aspergillus Infection →
Febrile Neutropenia — all drugs for Febrile Neutropenia →
Candida Infection — all drugs for Candida Infection →
Fungal Infection — all drugs for Fungal Infection →

Sponsor

Taiwan Liposome Company — full company profile →

Who can join

2 and older, any sex, with Aspergillus Infection or Febrile Neutropenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A retrospective, post-marketing, multi-center chart review study includes patients who had been prescribed Ampholipad.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Aspergillus Infection

Currently open trials in the same condition.

NCT07440485 — Aspergillus Infection in Patients Admitted to Hematology Ward · recruiting

Other Taiwan Liposome Company trials

Trials by the same sponsor.

NCT04697654 — The Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers · Phase 1 · completed
NCT04123561 — Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain · Phase 3 · completed
NCT03838133 — A Study to Evaluate Safety, PK, Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy · Phase 2 · completed
NCT03754049 — A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee · Phase 2 · completed
NCT03591146 — Phase I/II Dose-escalation Study to Evaluate Safety, PK and Efficacy of TLC590 for Postsurgical Pain Management · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03641131 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Taiwan Liposome Company
Last refreshed: 7 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03641131.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing